Candida auris (C. auris)According to Centers for Disease Control and Prevention (CDC) data published in the Annals of Internal Medicine, a new fungus considered an urgent antimicrobial resistance (AR) threat will enter U.S. health care facilities in 2020-2021. spread with astonishing speed. Equally concerning is the tripled number of echinocandin-resistant cases in 2021. C. auris Infection. in general, C. auris Not a threat to healthy people.People who are very sick, have invasive medical devices, or have long or frequent stays in medical facilities are at higher risk of infection C. aurisdetermined by the CDC C. auris It is often resistant to multiple antifungal drugs, spreads easily in health care facilities, and can cause severe infections with high mortality rates, making it an urgent AR threat.
CDC epidemiologist Dr. Megan Lyman, lead author of the paper, said: .
As further explained in the article, C. auris Since first reported in 2016, it has spread in the United States, with a total of 3,270 clinical cases (infection present) and 7,413 screening cases (fungi detected but not causing infection) by December 31, 2021. None) have been reported, with clinical cases increasing annually since 2016, with the fastest increase between 2020 and 2021. The CDC says he continues to increase the number of cases in 2022. First in 17 states between 2019 and 2021 C. auris case ever. The number of clinical cases nationwide increased from 476 in 2019 to 1,471 in 2021. Screened cases tripled from 2020 to 2021, bringing the total to 4,041. Screening is important to prevent spread by identifying patients with the fungus so that infection control controls can be used.
C. auris The number of cases is increasing for many reasons, including poor general infection prevention and control (IPC) practices in health care facilities. Efforts to detect cases, such as increased colonization screening, which is a test to see if an infected person has the fungus anywhere on their body but does not have an infection or symptoms of an infection. may have also increased due to the enhancement of The timing of this increase and the results of public health surveys C. auris The strain on medical and public health systems during the COVID-19 pandemic may have exacerbated the spread of infection.
CDC’s Antimicrobial Resistance Laboratory Network provides national laboratory capabilities to rapidly detect antimicrobial resistance, contain the spread, and inform local responses to protect people; provided some. Through supplemental funding supported by the Rescue Plans Act of America, CDC has worked to significantly strengthen the capacity of laboratories, including state, territory, and local health departments.These efforts include improving susceptibility testing capabilities. C. auris From 7 regional labs to 26+ labs nationwide.
CDC continues to work with state, local and territory health departments and other partners to address this emerging threat to public health. For more information, C. aurisidentified antimicrobial resistance threat reports C. auris As an urgent threat to the United States or the WHO Priority Fungal Pathogen List identify C. auris as a global priority.